Trial · NCT01265940
Pazopanib and Vinflunine in Urothelial Cancer of the Bladder
NCT01265940, Phase 1, Phase 2, Completed, Prof. Dr. Thomas Otto
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pazopanib and Vinflunine in Urothelial Cancer of the Bladder. Trials, record NCT01265940. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01265940
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pazopanib and Vinflunine in Urothelial Cancer of the Bladder
- NCT number
- NCT01265940
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 5 participants, actual
- Lead sponsor
- Prof. Dr. Thomas Otto
- Conditions
- Advanced Urothelial Cancer of Bladder After Failure of Platinum-containing Therapy.
- Interventions
- Pazopanib as add-on to vinflunine
- First posted
- 2010-12-23
- Last updated
- 2012-10-10
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Phase I: Definition of the Maximum Tolerated Dose (MTD) of Pazopanib in combination with Vinflunine. | 6 weeks (two cycles of vinflunine) | MTD ist defined as the dose level with dose-limiting toxicity occurring in maximum one out of six patients. |
| Primary | Phase II: Progression-free survival rate | 3 months | Progression-free survival will be assessed by means of RECIST 1.1. methodology |
| Secondary | Phase I: Progression-free survival rate, Phase II: Safety profile, overall survival | Six weeks after first administration of study drug. | Progression-free survival will be assessed by means of RECIST 1.1. methodology |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01265940
GET https://conductscience.org/api/trials/v1/NCT01265940/registered